This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Are There Any Dividend-Paying Cannabis Stocks?
by Ryan McQueeney
Cannabis stocks have been one of the investing world's top stories in 2018, but for many, these speculative plays are far too unpredictable. Are there any stable, dividend-paying marijuana stocks to buy right now?
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $102.94, moving +0.48% from the previous trading session.
Options Traders Expect Huge Moves in Tilray (TLRY) Stock
by Zacks Equity Research
Tilray (TLRY) needs investors to pay close attention to the stock based on moves in the options market lately.
Legal Pot Shops & Likely IPOs: Is Hemp the Next Big Thing?
by Nitish Marwah
Increasing tolerance and gradual legalization of marijuana has been an increasing trend across America.
Top and Flop ETFs of Last Week
by Sanghamitra Saha
Inside the winning and losing ETFs of the last week.
What Went Wrong With the Marijuana ETF on Wednesday?
by Sanghamitra Saha
Downbeat earnings have weighed on the marijuana ETF lately. Should you buy the dip or wait on the sidelines?
Cannabis Stocks Reporting Earnings & News from HD, AAPL, TSN
by Ryan McQueeney
Ryan McQueeney discusses the latest trade war developments and recaps earnings results from Home Depot and Tyson Foods. He also touches on Apple's supplier concerns. Later, the host chats with Dave Bartosiak about the marijuana stocks reporting earnings this week.
Cronos (CRON) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.
The Earnings Charts of 3 Top Cannabis Stocks
by Tracey Ryniec
The cannabis stocks are hot but will their earnings reports be too?
The Zacks Analyst Blog Highlights: Tilray, Walmart and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Walmart and NVIDIA
Upcoming Earnings to Watch: TLRY, WMT, NVDA
by Ryan McQueeney
U.S. stocks fell sharply in morning trading, as concerns about slumping oil prices, a hotter-than-expected PPI, and a more hawkish Fed cooled Wall Street's post-election bullishness. Investors will now turn to the last wave of Q3 earnings reports for clues on what is next for this market
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
Why Marijuana Stocks & ETF Soared Today
by Neena Mishra
Pot stocks soared today as Jeff Sessions' exit and midterm elections have created a more favorable political environment for the industry.
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $100.98 in the latest trading session, marking a +1.5% move from the prior day.
Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $90.41 in the latest trading session, marking a -0.3% move from the prior day.
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
Tilray, Inc. (TLRY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $120.79, marking a -1.48% move from the previous day.
Marijuana ETF Enters Bear Territory: What Lies Ahead?
by Sweta Killa
Despite entering into bear territory, the cannabis ETF is up more than 24% over the past three months and the outlook remains bright.
Marijuana Stocks Plummet to Record Low: What's Next?
by Zacks Equity Research
Legalization has long been considered a boon for the marijuana industry.
The Zacks Analyst Blog Highlights: Tilray, Coca-Cola, Constellation Brands, Canopy Growth and ETFMG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Coca-Cola, Constellation Brands, Canopy Growth and ETFMG
Canada Legalizes Marijuana: Stocks & ETF in Focus
by Neena Mishra
Canada legalized recreational pot today but it's "sell the news" event for pot stocks that have seen astronomical gains recently.
Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.